"10.1371_journal.pone.0074314","plos one","2013-09-26T00:00:00Z","Freddie M Kibengo; Eugene Ruzagira; David Katende; Agnes N Bwanika; Ubaldo Bahemuka; Jessica E Haberer; David R Bangsberg; Burc Barin; James F Rooney; David Mark; Paramesh Chetty; Patricia Fast; Anatoli Kamali; Frances H Priddy","Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) Uganda Research Unit on AIDS, Entebbe, Uganda; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America; The EMMES Corporation, Rockville, Maryland, United States of America; Gilead, Foster City, California, United States of America; International AIDS Vaccine Initiative, Nairobi, Kenya; International AIDS Vaccine Initiative, Johannesburg, South Africa; International AIDS Vaccine Initiative, New York, New York, United States of America","Conceived and designed the experiments: AK JEH DRB BB PF FHP DM. Performed the experiments: FMK ER DK UB ANB PC. Analyzed the data: BB. Contributed reagents/materials/analysis tools: DM JFR. Wrote the manuscript: FMK ER DK ANB UB AK JEH DRB BB JFR PF FHP. N/A.","Gilead Sciences provided the study drug and placebo tablets at no cost. Co-author James Rooney is employed by Gilead Sciences. Gilead Sciences developed and is marketing the study drug, Truvada, for treatment of HIV infection. Co-author Burc Barin is employed by the EMMES Corporation, and does not have any relevant declarations relating to consultancy, patents, products in development or marketed products. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","09","Freddie M Kibengo","FMK",14,TRUE,7,6,1,12,TRUE,FALSE,FALSE,0,NA,FALSE
